Ability Biologics dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need..
Ability biologics has raised $18.0M in total funding. The most recent round was Seed. The last funding was announced in June 2024.
Ability biologics's investors include Fonds de solidarité FTQ, Charles River Laboratories International, Alexandria Venture Investments, Investissement Quebec, Amplitude Venture Capital.
Ability biologics is headquartered in Ville-marie, Canada.
Ability Biologics dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need..
Ability biologics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ability biologics — Funding & Investors." VCBacked, June 18, 2024, https://www.vcbacked.co/company/ability-biologics. Accessed September 20, 2026.
VCBacked. (2024). Ability biologics — Funding & Investors. Retrieved September 20, 2026, from https://www.vcbacked.co/company/ability-biologics
{{cite web |title=Ability biologics — Funding & Investors |url=https://www.vcbacked.co/company/ability-biologics |website=VCBacked |access-date=September 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated